Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arvinas, Inc. (ARVN : NSDQ)

• Company Description    Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. Number of Employees: 430

• Price / Volume Information    Yesterday's Closing Price: $10.63 Daily Weekly Monthly 20 Day Moving Average: 2,617,092 shares Shares Outstanding: 64.22 (millions) Market Capitalization: $682.70 (millions) Beta: 2.38 52 Week High: $28.70 52 Week Low: $5.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.37% 9.42% 12 Week 49.93% 43.71% Year To Date -44.55% -51.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5 SCIENCE PARK 395 WINCHESTER AVENUE - NEW HAVEN,CT 06511 USA ph: 203-535-1456 fax: - ir@arvinas.com http://www.arvinas.com

• General Corporate Information    Officers John Houston - President; Chief Executive Officer and Chairman Andrew Saik - Chief Financial Officer and Treasurer David K. Loomis - Vice President and Chief Accounting Officer Sunil Agarwal - Director Linda Bain - Director Peer Information Arvinas, Inc. (CORR.) Arvinas, Inc. (RSPI) Arvinas, Inc. (CGXP) Arvinas, Inc. (BGEN) Arvinas, Inc. (GTBP) Arvinas, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04335A105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/10/26 Share - Related Items Shares Outstanding: 64.22 Most Recent Split Date: (:1) Beta: 2.38 Market Capitalization: $682.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.38 Price/Cash Flow: - Price / Sales: 2.19 EPS Growth vs. Year Ago Period: 29.41% vs. Previous Quarter: 42.86% Sales Growth vs. Year Ago Period: -59.08% vs. Previous Quarter: 87.05% ROE 09/30/25 - -9.77 06/30/25 - -12.01 03/31/25 - -7.74 ROA 09/30/25 - -6.08 06/30/25 - -6.97 03/31/25 - -4.11 Current Ratio 09/30/25 - 5.70 06/30/25 - 5.64 03/31/25 - 4.58 Quick Ratio 09/30/25 - 5.70 06/30/25 - 5.64 03/31/25 - 4.58 Operating Margin 09/30/25 - -18.73 06/30/25 - -19.47 03/31/25 - -10.92 Net Margin 09/30/25 - -18.73 06/30/25 - -19.47 03/31/25 - -10.92 Pre-Tax Margin 09/30/25 - -18.76 06/30/25 - -19.42 03/31/25 - -10.75 Book Value 09/30/25 - 7.69 06/30/25 - 8.35 03/31/25 - 9.04 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.07 06/30/25 - 0.08 03/31/25 - 0.08

Powered by Zacks Investment Research ©